LZAGY
Lonza Group AG
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synth
